Direct Detection of Antibiotic Resistance in Chinese Helicobacter pylori Clinical Isolates by Sequencing-Based Approach

J Healthc Eng. 2022 Apr 15:2022:6436256. doi: 10.1155/2022/6436256. eCollection 2022.

Abstract

Objective: The detection of Helicobacter pylori mutations that result in antimicrobial resistance can serve as a guideline of antimicrobial therapeutics and probably prevent the failure of clinical treatments. Evaluating the potential of Sanger sequencing to identify genetically resistant determinants in Helicobacter pylori clinical isolates will be important.

Methods: 180 cultured strains have been tested using agar dilution for antibiotic susceptibility. NCBI BLAST was used to perform genotypic analysis on the sequencing data. Sanger sequencing was evaluated as an alternative method to detect resistant genotypes and susceptibility.

Results: By the conventional E-test, resistance to levofloxacin, amoxicillin, metronidazole, and clarithromycin was 67.3%, 15.1%, 96.4%, and 25.5%, respectively. In contrast, tetracycline had no resistance. Resistance to multiple drugs was observed in 8.12% of the strains. The genetic determinants of resistance to CLA was 23s rRNA, the determinants of resistance to amoxicillin was Pbp1, the determinants of resistance to metronidazole was rdxA, and the determinants of resistance to levofloxacin were GyrA and GyrB. However, there was no association of resistance in tetracycline.

Conclusion: We found increased rates of metronidazole antibiotic resistance, highlighting the necessity for alternative therapies and periodic evaluation. Sanger sequencing has proved to be highly effective and holds the potential to be implemented in policies catering to local treatments.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Amoxicillin / pharmacology
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • China
  • Clarithromycin / pharmacology
  • Clarithromycin / therapeutic use
  • Drug Resistance, Microbial
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / genetics
  • Helicobacter pylori* / genetics
  • Humans
  • Levofloxacin / pharmacology
  • Levofloxacin / therapeutic use
  • Metronidazole / pharmacology
  • Metronidazole / therapeutic use
  • Microbial Sensitivity Tests
  • Tetracycline / pharmacology
  • Tetracycline / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Metronidazole
  • Levofloxacin
  • Amoxicillin
  • Tetracycline
  • Clarithromycin